In summary, combination of dovitinib and oxaliplatin produced a synergistic effect in colon cancer cells regardless of their RAS-RAF/p53 mutation status and also in a multidrug resistant clone of colon cancer model. The gene discussed is TP53; the disease is malignant colon neoplasm.